Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Stock Up 6.7 Percent After Firm Wins 6 New US Patents

NEW YORK (GenomeWeb News) – Shares in Nanogen were up 6.7 percent, or $.12, at $1.92 in early-afternoon trading after the company said it won six US patents covering inventions related to diabetes and Alzheimer’s disease and biomarkers.

US Patent Nos. 7,052,849, "Protein biopolymer markers predictive of insulin resistance;" 7,049,397, "Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons;" and 7,087,435, "Biopolymer marker indicative of disease state having a molecular weight of 2735 daltons," relate to the use of mass spectrometry and time-of-flight detection “to identify various biomarkers such as those associated with metabolic Syndrome X and conditions linked to Syndrome X.”

Patent Nos. 7,026,129, "IG lambda biopolymer markers predictive of Alzheimer’s disease," and 7,074,576, "Protein biopolymer markers indicative of Alzheimer’s disease," relate to the use of mass spec and time-of-flight detection measures to elucidate biopolymer markers associated with Alzheimer’s disease and Syndrome X. 

Patent No. 7,070,945, "Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment," claims a method for using a biochemical marker to identify patients with mild cognitive impairment “who have a likelihood of progressing to Alzheimer’s disease."